Developer docs
API playgroundTry for free, no card

Search company profiles

NovaSight

Full company profile

uuid00026hb

Namestring
NovaSight
Legal namestring
NovaSight Ltd.
Websiteurl
nova-sight.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

NovaSight Ltd. is an Israeli medical technology company developing eye-tracking-based digital solutions for pediatric vision care. Founded in 2016 and headquartered in Airport City, Israel, with a US office in Lewes, Delaware, the company targets two large unmet needs: amblyopia (lazy eye), which affects approximately 3% of children globally, and pediatric myopia prevention linked to excessive screen time. The flagship commercial product, CureSight, is an FDA 510(k)-cleared (K213615) and CE-marked digital therapy that treats amblyopia in children aged 4-9 by tracking eye gaze 90 times per second via optical image sensors and presenting dichoptic images through red-blue anaglyph glasses while patients watch streamed content (Netflix, YouTube, Disney+). The pipeline includes TrackSight, a SaaS solution using embedded webcams for myopia prevention, which is not yet approved for sale in any country.

The technology platform rests on proprietary eye-tracking hardware—including ActiveSight LCD Active Shutter Glasses designed for children and the EyeSwift PRO diagnostic system—combined with cloud-connected software that performs real-time dichoptic image processing. NovaSight's pivotal trial demonstrated that 79% of CureSight patients achieved 2+ line visual acuity improvement versus 61% for patching (p<0.05) in a 103-patient study across six medical centers, with 93% adherence and 95% parental preference. The company operates a US-based CureSight Monitoring Center directed by practicing ophthalmologists that handles patient onboarding, device logistics, compliance monitoring, technical support, billing, and prior authorization support, with infrastructure support from partner Notal Vision.

NovaSight's business model combines device provision with subscription-style recurring revenue billed through three unique Category III CPT codes (0704T for device setup, 0705T for monthly surveillance, 0706T for physician interpretation) assigned by the American Medical Association. CureSight is prescribed exclusively through eye care providers (ophthalmologists and optometrists) via a dedicated web portal and referral program, with reimbursement currently secured through Anthem Blue Cross Blue Shield (since April 2025) and Aetna (since July 2025). The company has raised $8 million in Series A financing (July 2020) plus $1 million in grants from the Israel Innovation Authority, and distributes its vision assessment technology internationally through a partnership with Essilor.

Short descriptiontext

NovaSight is an Israeli medical technology company developing FDA-cleared, eye-tracking-based digital therapies for pediatric vision care. Its flagship CureSight system treats amblyopia in children aged 4-9 via dichoptic streamed content, with a TrackSight SaaS pipeline targeting myopia prevention.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTel Aviv, Israel
HQ citystring
Tel Aviv
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
amblyopia treatment systems, eye tracking technology, pediatric vision care, digital vision therapy, myopia prevention software
Industry4 codes
PRIMARYHLAHAJAM
Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAM
Vision Therapy & Orthoptics
SECONDARYHLAHAJAC
Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAK
Contact Lens Specialty & Myopia Control
NAICS code1 code
  • Ophthalmic Goods Manufacturing339115
SIC code1 code
  • Ophthalmic Goods3851
Product category
Pediatric Ophthalmology Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1CureSight Device and Monitoring (US)
TypeSubscription Recurring
Description

CureSight treatment is billed through three unique Category III CPT codes: 0704T (device supply, initial set-up and patient education), 0705T (surveillance center technical support and data transmission, each 30 days), and 0706T (interpretation and report by physician, per calendar month). The Monitoring Center bills for 0704T and 0705T; the clinic bills for 0706T. Insurance coverage is available through Anthem Blue Cross Blue Shield and Aetna for eligible patients. Treatment requires minimum 90 minutes per day, 5 days a week, over a physician-determined duration.

nova-sight.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1Device setup, monitoring, and physician interpretation billed through CPT codes
ModelSubscriptionBilling cadenceMonthly
Notes

Three CPT codes govern billing: 0704T for device supply and initial setup, 0705T for monthly surveillance center technical support, and 0706T for physician interpretation per calendar month. Reimbursement varies by payor and plan. Coverage available through Anthem Blue Cross Blue Shield and Aetna for eligible patients.

nova-sight.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NovaSight develops and sells the FDA-cleared CureSight digital amblyopia (lazy eye) treatment system for children aged 4-9, which uses eye-tracking-based real-time dichoptic image processing with red-blue anaglyph glasses while patients watch streamed content at home. The company also develops the TrackSight SaaS platform for myopia prevention using webcam-based eye-tracking, supported by the proprietary EyeSwift PRO diagnostic system and ActiveSight LCD shutter glasses for objective pediatric vision assessment.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 79% of CureSight patients achieved 2-line or more visual acuity improvement vs 61% for patching (p<0.05) at week 16 in pivotal trial
+4 more records
Product overview1 text field

NovaSight offers integrated eye-tracking-based solutions for pediatric vision assessment and treatment. The core portfolio consists of two main products: CureSight (FDA-cleared amblyopia treatment) and TrackSight (myopia prevention, in development). CureSight uses specialized ActiveSight glasses and a dedicated Monitoring Center to deliver binocular vision therapy via streamed content, while TrackSight uses webcam-based eye-tracking on consumer devices. Both products are supported by the EyeSwift PRO diagnostic platform and a cloud-based web portal for eye care providers.

Product and service3 records
1CureSight
CategoryPediatric Vision Care Device
Description

FDA 510(k)-cleared and CE-marked eye-tracking-based digital therapy system for pediatric amblyopia (lazy eye) in children aged 4-9. Uses red-blue anaglyph glasses with any streamed content (Netflix, YouTube, Disney+) while tracking eye movement at 90Hz to deliver real-time dichoptic images that stimulate the amblyopic eye. Treatment is remotely supervised by an eye care provider and NovaSight's US Monitoring Center.

2TrackSight
CategoryMyopia Prevention Software
Description

SaaS solution for myopia prevention and vision health monitoring that uses computer monitors' embedded webcams to perform eye-tracking and apply real-time peripheral blur based on momentary gaze position during screen time on laptops and tablets.

3ActiveSight Glasses
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Essilor, a global leader in ophthalmic optics with market cap of around $64 billion, approximately 70,000 employees, 32 plants, and 14 distribution centers in over 100 countries, distributes NovaSight's vision assessment technology. Essilor launched NovaSight's vision assessment system at the French Ophthalmology Society (SFO) Meeting in Paris in 2019. Essilor's global distribution network provides NovaSight with broad market reach in the ophthalmic optics space.

Strategic tierCoreTypeTechnology or Integration
Description

Tobii is the global leader in eye tracking, operating through three business units: Tobii Dynavox (assistive technology), Tobii Pro (research equipment used by 3,500 companies and 2,500 research institutions), and Tobii Tech (volume markets including healthcare). NovaSight's partnership with Tobii leverages Tobii's eye-tracking technology for healthcare applications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

EIT Health is a consortium leveraging expertise of over 140 leading organizations across key areas of healthcare, chosen by the European Institute of Innovation and Technology. With a budget of 2 billion euros (partially from Horizon2020), EIT Health invests in Europe's best entrepreneurial talents for development and commercialization of smart health products. NovaSight benefits from EIT Health's pan-European network and resources for healthcare innovation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Notal Vision provides the Notal Vision Monitoring Center, a full-service ophthalmic monitoring center directed by practicing ophthalmologists and supported by certified ophthalmic professionals. As a Medicare-credentialed digital healthcare provider, Notal Vision offers comprehensive patient education, training, and monitoring. NovaSight's CureSight Monitoring Center is supported by Notal Vision's infrastructure for remote patient monitoring and compliance tracking.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Ophthalmic lens and vision-care incumbent with growing myopia-management presence; relevant comparator for NovaSight's planned TrackSight myopia prevention entry.

TypeDirect peer
Description

Luminopia develops FDA-cleared dichoptic digital therapy for amblyopia in children, competing head-to-head with NovaSight's CureSight in the same pediatric ophthalmology/optometry channel using a similar mechanism of modified streamed content.

TypeBroad incumbent
Description

Diversified ophthalmic goods and vision-care incumbent with a pediatric vision franchise; provides broad context for competitive and reimbursement dynamics facing NovaSight's specialty amblyopia therapy.

TypeBroad incumbent
Description

Global leader in ophthalmic surgical and vision-care products, including pediatric and refractive solutions; competes for physician mindshare and formulary access that NovaSight must win to scale CureSight.

5Carl Zeiss Meditec
TypeBroad incumbent
Description

Broad ophthalmic diagnostics and surgical device incumbent whose vision-assessment and diagnostic portfolio overlaps with NovaSight's EyeSwift PRO-based pediatric screening offering.

TypeBroad incumbent
Description

CooperVision's SightGlass Vision division develops pediatric myopia-control products; directly relevant TrackSight comparator targeting the same eye-care providers and myopia-prevention use case.

TypeDirect peer
Description

Operates a Medicare-credentialed ophthalmic monitoring center that underpins NovaSight's CureSight Monitoring Center; competes more broadly in remote ophthalmic monitoring services and infrastructure.

TypeEmerging player
Description

Eye-tracking-based vision and health assessment platform used in optometry and pediatrics; overlaps with NovaSight's EyeSwift PRO in objective vision screening and tracking-based diagnostics.

TypeEmerging player
Description

US specialty provider network focused on children's myopia management; a relevant commercial-channel comparator for NovaSight's TrackSight go-to-market into pediatric eye-care practices.

TypeEmerging player
Description

Developer of portable ophthalmic diagnostic devices including pediatric vision screening tools; comparable to NovaSight's EyeSwift PRO-based objective pediatric assessment offering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NovaSight

Pediatric Ophthalmology Medical Devicesnova-sight.com

NovaSight is an Israeli medical technology company developing FDA-cleared, eye-tracking-based digital therapies for pediatric vision care. Its flagship CureSight system treats amblyopia in children aged 4-9 via dichoptic streamed content, with a TrackSight SaaS pipeline targeting myopia prevention.

What NovaSight does

NovaSight Ltd. is an Israeli medical technology company developing eye-tracking-based digital solutions for pediatric vision care. Founded in 2016 and headquartered in Airport City, Israel, with a US office in Lewes, Delaware, the company targets two large unmet needs: amblyopia (lazy eye), which affects approximately 3% of children globally, and pediatric myopia prevention linked to excessive screen time. The flagship commercial product, CureSight, is an FDA 510(k)-cleared (K213615) and CE-marked digital therapy that treats amblyopia in children aged 4-9 by tracking eye gaze 90 times per second via optical image sensors and presenting dichoptic images through red-blue anaglyph glasses while patients watch streamed content (Netflix, YouTube, Disney+). The pipeline includes TrackSight, a SaaS solution using embedded webcams for myopia prevention, which is not yet approved for sale in any country.

The technology platform rests on proprietary eye-tracking hardware—including ActiveSight LCD Active Shutter Glasses designed for children and the EyeSwift PRO diagnostic system—combined with cloud-connected software that performs real-time dichoptic image processing. NovaSight's pivotal trial demonstrated that 79% of CureSight patients achieved 2+ line visual acuity improvement versus 61% for patching (p<0.05) in a 103-patient study across six medical centers, with 93% adherence and 95% parental preference. The company operates a US-based CureSight Monitoring Center directed by practicing ophthalmologists that handles patient onboarding, device logistics, compliance monitoring, technical support, billing, and prior authorization support, with infrastructure support from partner Notal Vision.

NovaSight's business model combines device provision with subscription-style recurring revenue billed through three unique Category III CPT codes (0704T for device setup, 0705T for monthly surveillance, 0706T for physician interpretation) assigned by the American Medical Association. CureSight is prescribed exclusively through eye care providers (ophthalmologists and optometrists) via a dedicated web portal and referral program, with reimbursement currently secured through Anthem Blue Cross Blue Shield (since April 2025) and Aetna (since July 2025). The company has raised $8 million in Series A financing (July 2020) plus $1 million in grants from the Israel Innovation Authority, and distributes its vision assessment technology internationally through a partnership with Essilor.

NovaSight firmographics

Firmographics
Name
NovaSight
Legal name
NovaSight Ltd.
Website
https://nova-sight.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
NovaSight is an Israeli medical technology company developing FDA-cleared, eye-tracking-based digital therapies for pediatric vision care. Its flagship CureSight system treats amblyopia in children aged 4-9 via dichoptic streamed content, with a TrackSight SaaS pipeline targeting myopia prevention.
Ownership category
akta.pro rank

NovaSight industry classification

Industry
Product category
Pediatric Ophthalmology Medical Devices
NAICS
Ophthalmic Goods Manufacturing (339115)
SIC
Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAHAJAM
Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAM
Vision Therapy & Orthoptics
SECONDARYHLAHAJAC
Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAK
Contact Lens Specialty & Myopia Control

Keywords

  • Amblyopia treatment systems
  • Eye tracking technology
  • Pediatric vision care
  • Digital vision therapy
  • Myopia prevention software

Where NovaSight is headquartered

Location

Headquarters

HQ city
Tel Aviv
HQ country
Israel
HQ region
Middle East

Offices2 records

Markets served

NovaSight business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. CureSight Device and Monitoring (US): CureSight treatment is billed through three unique Category III CPT codes: 0704T (device supply, initial set-up and patient education), 0705T (surveillance center technical support and data transmission, each 30 days), and 0706T (interpretation and report by physician, per calendar month). The Monitoring Center bills for 0704T and 0705T; the clinic bills for 0706T. Insurance coverage is available through Anthem Blue Cross Blue Shield and Aetna for eligible patients. Treatment requires minimum 90 minutes per day, 5 days a week, over a physician-determined duration.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyDevice setup, monitoring, and physician interpretation billed through CPT codes

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

NovaSight product offering

Product offering

Core offering

NovaSight develops and sells the FDA-cleared CureSight digital amblyopia (lazy eye) treatment system for children aged 4-9, which uses eye-tracking-based real-time dichoptic image processing with red-blue anaglyph glasses while patients watch streamed content at home. The company also develops the TrackSight SaaS platform for myopia prevention using webcam-based eye-tracking, supported by the proprietary EyeSwift PRO diagnostic system and ActiveSight LCD shutter glasses for objective pediatric vision assessment.

Product overview

NovaSight offers integrated eye-tracking-based solutions for pediatric vision assessment and treatment. The core portfolio consists of two main products: CureSight (FDA-cleared amblyopia treatment) and TrackSight (myopia prevention, in development). CureSight uses specialized ActiveSight glasses and a dedicated Monitoring Center to deliver binocular vision therapy via streamed content, while TrackSight uses webcam-based eye-tracking on consumer devices. Both products are supported by the EyeSwift PRO diagnostic platform and a cloud-based web portal for eye care providers.

Differentiator

Problem solved

Functional benefit

Products and services

  • CureSight FDA 510(k)-cleared and CE-marked eye-tracking-based digital therapy system for pediatric amblyopia (lazy eye) in children aged 4-9. Uses red-blue anaglyph glasses with any streamed content (Netflix, YouTube, Disney+) while tracking eye movement at 90Hz to deliver real-time dichoptic images that stimulate the amblyopic eye. Treatment is remotely supervised by an eye care provider and NovaSight's US Monitoring Center.
  • TrackSight SaaS solution for myopia prevention and vision health monitoring that uses computer monitors' embedded webcams to perform eye-tracking and apply real-time peripheral blur based on momentary gaze position during screen time on laptops and tablets.
  • ActiveSight Glasses

Quantifiable outcome

  • 79% of CureSight patients achieved 2-line or more visual acuity improvement vs 61% for patching (p<0.05) at week 16 in pivotal trial
  • +4 more outcomes

Companies that use NovaSight

Customer profile

Named customers6 records

Segments1 record

Ideal customer profiles1 record

NovaSight technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability6 records

Feature4 records

NovaSight partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • EssilorcoreChannel Partner/ Reseller/ DistributorEssilor, a global leader in ophthalmic optics with market cap of around $64 billion, approximately 70,000 employees, 32 plants, and 14 distribution centers in over 100 countries, distributes NovaSight's vision assessment technology. Essilor launched NovaSight's vision assessment system at the French Ophthalmology Society (SFO) Meeting in Paris in 2019. Essilor's global distribution network provides NovaSight with broad market reach in the ophthalmic optics space.
  • TobiicoreTechnology or IntegrationTobii is the global leader in eye tracking, operating through three business units: Tobii Dynavox (assistive technology), Tobii Pro (research equipment used by 3,500 companies and 2,500 research institutions), and Tobii Tech (volume markets including healthcare). NovaSight's partnership with Tobii leverages Tobii's eye-tracking technology for healthcare applications.
  • EIT HealthcoreStrategic or Co-development PartnerEIT Health is a consortium leveraging expertise of over 140 leading organizations across key areas of healthcare, chosen by the European Institute of Innovation and Technology. With a budget of 2 billion euros (partially from Horizon2020), EIT Health invests in Europe's best entrepreneurial talents for development and commercialization of smart health products. NovaSight benefits from EIT Health's pan-European network and resources for healthcare innovation.
  • Notal VisioncoreStrategic or Co-development PartnerNotal Vision provides the Notal Vision Monitoring Center, a full-service ophthalmic monitoring center directed by practicing ophthalmologists and supported by certified ophthalmic professionals. As a Medicare-credentialed digital healthcare provider, Notal Vision offers comprehensive patient education, training, and monitoring. NovaSight's CureSight Monitoring Center is supported by Notal Vision's infrastructure for remote patient monitoring and compliance tracking.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

NovaSight competitors and assessment

Company assessment

Broad incumbents

  • HOYA Vision Care: Ophthalmic lens and vision-care incumbent with growing myopia-management presence; relevant comparator for NovaSight's planned TrackSight myopia prevention entry.
  • Bausch + Lomb: Diversified ophthalmic goods and vision-care incumbent with a pediatric vision franchise; provides broad context for competitive and reimbursement dynamics facing NovaSight's specialty amblyopia therapy.
  • Alcon: Global leader in ophthalmic surgical and vision-care products, including pediatric and refractive solutions; competes for physician mindshare and formulary access that NovaSight must win to scale CureSight.
  • Carl Zeiss Meditec: Broad ophthalmic diagnostics and surgical device incumbent whose vision-assessment and diagnostic portfolio overlaps with NovaSight's EyeSwift PRO-based pediatric screening offering.
  • CooperVision (SightGlass Vision): CooperVision's SightGlass Vision division develops pediatric myopia-control products; directly relevant TrackSight comparator targeting the same eye-care providers and myopia-prevention use case.

Direct peers

  • Luminopia: Luminopia develops FDA-cleared dichoptic digital therapy for amblyopia in children, competing head-to-head with NovaSight's CureSight in the same pediatric ophthalmology/optometry channel using a similar mechanism of modified streamed content.
  • Notal Vision: Operates a Medicare-credentialed ophthalmic monitoring center that underpins NovaSight's CureSight Monitoring Center; competes more broadly in remote ophthalmic monitoring services and infrastructure.

Emerging players

  • RightEye: Eye-tracking-based vision and health assessment platform used in optometry and pediatrics; overlaps with NovaSight's EyeSwift PRO in objective vision screening and tracking-based diagnostics.
  • Treehouse Eyes: US specialty provider network focused on children's myopia management; a relevant commercial-channel comparator for NovaSight's TrackSight go-to-market into pediatric eye-care practices.
  • Adaptica: Developer of portable ophthalmic diagnostic devices including pediatric vision screening tools; comparable to NovaSight's EyeSwift PRO-based objective pediatric assessment offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

NovaSight social profiles

Digital presence

NovaSight compliance and trust

Trust signal

Compliance4 records

NovaSight financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NovaSight leadership team

Management profile

Number of profiles

Profiles6 records

NovaSight funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NovaSight M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NovaSight

What does NovaSight do?

NovaSight develops and sells the FDA-cleared CureSight digital amblyopia (lazy eye) treatment system for children aged 4-9, which uses eye-tracking-based real-time dichoptic image processing with red-blue anaglyph glasses while patients watch streamed content at home. The company also develops the TrackSight SaaS platform for myopia prevention using webcam-based eye-tracking, supported by the proprietary EyeSwift PRO diagnostic system and ActiveSight LCD shutter glasses for objective pediatric vision assessment.

Is NovaSight a public or private company?

NovaSight is a private company. It is classified as venture growth investor backed and is currently operating.

When was NovaSight founded?

NovaSight was founded in 2016. It employs 11 to 50 people.

Where is NovaSight based?

NovaSight is headquartered in Tel Aviv, Israel, in the Middle East region.

How does NovaSight make money?

One revenue line is on record: cureSight Device and Monitoring (US).

Who are NovaSight's main competitors?

Broad incumbents on record are HOYA Vision Care, Bausch + Lomb, Alcon, Carl Zeiss Meditec and CooperVision (SightGlass Vision). Direct peers are Luminopia and Notal Vision. Emerging players are RightEye, Treehouse Eyes and Adaptica.

Does NovaSight have an API?

No public API is recorded for NovaSight.

What industry is NovaSight in?

NovaSight's product category is Pediatric Ophthalmology Medical Devices. Its primary akta.pro industry code is HLAHAJAM, Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment), with a secondary code of HLAKAKAM, Vision Therapy & Orthoptics. Its NAICS code is 339115 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TimesofisraelThe Blogs: Rebooting the Lazy Eye: How Israeli Startups Are Retiring the Pirate PatchIsraeli startups NovaSight, Medisim, and Dr. Omry Ben-Ezra (Amblyz) are developing digital alternatives to the traditional adhesive eye patch for treating amblyopia (lazy eye) in children, with NovaSight's FDA-cleared CureSight system demonstrating 79% visual acuity improvement versus 61% for patching in a pivotal 103-patient trial, while achieving 93% patient adherence through streaming content viewed through red-blue treatment glasses with AI eye-tracking. MIT neuroscientists published research in December 2025 showing that briefly anesthetising the retina of the amblyopic eye for 48 hours could restore balanced visual input in adult mice, potentially dissolving the age barrier that currently limits treatment to young children. The global amblyopia treatment market, valued at over $4 billion, is projected to exceed $5.5 billion by the end of the decade.openPR.comTop Companies in the Amblyopia Treatment Market - NovaSight, Vivid Vision, AmblyoCare, RevitalVision, Orbis InternationalLeading amblyopia treatment companies including NovaSight, Vivid Vision, and AmblyoCare are profiled with their digital and VR-based strategies. The market is shifting toward integrated, technology-enabled therapeutic ecosystems, with investment flowing into VR therapies, neuroplasticity-driven approaches, and regional expansion in Asia-Pacific and Latin America.Nova-SightEye Tracking Based Vision Care SolutionsNovaSight has developed a pediatric vision care solution that combines eye-tracking technology with data analytics to enable remote digital treatment for conditions like amblyopia and myopia. The system utilizes active glasses and optical sensors to provide accurate, objective assessments without requiring patient cooperation or operator skills.ACCESS NewswireNovaSight Ltd. Achieves Major Milestone: Insurance Coverage Secured for Eye-Tracking-Based Digital Amblyopia TherapyNovaSight's FDA-cleared CureSight amblyopia therapy is now covered by Elevance Health (Anthem Blue Cross and Blue Shield) insurance plans. The coverage includes three CPT codes for the home-based digital treatment, expanding access for children aged 4-9. The company cites advocacy from the AAO and AAPOS in achieving this milestone.PharmiWeb.comNovaSight Ltd. Achieves Major Milestone: Insurance Coverage Secured for Eye-Tracking-Based Digital Amblyopia TherapyNovaSight's FDA-cleared CureSight amblyopia therapy is now covered by Elevance Health (Anthem Blue Cross and Blue Shield) insurance plans. The coverage includes three CPT codes for the device and physician services, expanding access for children aged 4-9. The company cites advocacy from the AAO and AAPOS as key to achieving this milestone.MorningstarNovaSight Ltd. Achieves Major Milestone: Insurance Coverage Secured for Eye-Tracking-Based Digital Amblyopia TherapyNovaSight's FDA-cleared CureSight amblyopia therapy is now covered by Anthem Blue Cross and Blue Shield (Elevance Health) insurance plans. The coverage includes three CPT codes for supply, installation, and physician services, expanding access for children aged 4-9. The company cites advocacy from the AAO and AAPOS.YahooNovaSight Ltd. Achieves Major Milestone: Insurance Coverage Secured for Eye-Tracking-Based Digital Amblyopia TherapyNovaSight Ltd. announced that its FDA-cleared CureSight™ eye-tracking-based digital therapy for amblyopia (lazy eye) is now covered by Anthem Blue Cross and Blue Shield (Elevance Health, Inc.) insurance plans, marking a pivotal milestone in pediatric vision care. The coverage, effective under Anthem's updated medical policy MED.00145, recognizes home-based digital treatments as medically necessary for children aged 4 to 9 years and includes three dedicated CPT codes. The American Academy of Ophthalmology and American Association for Pediatric Ophthalmology and Strabismus played critical advocacy roles in achieving this insurance coverage decision.Global leader in eye tracking for over 20 yearsTransform vision care with screen-based eye trackingNovaSight, Dive Medical Optics, and Optics Trainer have partnered with Tobii to integrate eye tracking technology into their vision care treatment solutions. This collaboration enables precise patient monitoring and engagement through screen-based visual exploration exercises. The integration is described as essential for creating objective medical devices and engaging therapy tools.Nova-SightFuture of Digital Amblyopia Treatment: Vision RevolutionNovaSight is promoting its digital amblyopia treatment platform, which utilizes gamified software and virtual reality to provide home-based vision therapy for children and adults. The company claims this approach offers faster results and higher patient engagement compared to traditional patching methods by stimulating binocular vision through interactive exercises.NoCamelsIsraeli 3D Glasses To Combat Lazy EyeNovaSight's CureSight treats lazy eye using red-blue glasses and a tablet that blurs the dominant eye's vision while streaming content. A clinical study found 79% of patients improved after four months, versus 61% for patch treatment. The device has EU certification and is launched in Italy, with over 75 American patients using it.